|
WO2016172517A1
|
|
Methods of treating prostate cancer
|
|
AU2014306698A1
|
|
Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies
|
|
AU2012358219A1
|
|
Methods and compositions for combination therapy using P13K/mTOR inhibitors
|
|
WO2013071177A1
|
|
Methods and compositions for inhibition of androgen receptor activity
|
|
CN103813794A
|
|
Novel compositions and methods for treating prostate cancer
|
|
AU2010319697A1
|
|
Mammalian metabolites of steroids
|
|
EP2461814A2
|
|
Treatment of prostate cancer
|
|
GB2479337A
|
|
Combination of a 17 alpha-hydroxylase/c17, 20-lyase inhibitor with an additional therapeutic agent
|
|
GB201114154D0
|
|
Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
|
|
AU2010210422A1
|
|
Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
|
